Neurotransmitter and psychostimulant recognition by the dopamine transporter

Nature

Volumn 521, Issue 7552, 2015, Pages 322-327

  Wang, Kevin H ^a,b   Penmatsa, Aravind ^a,c   Gouaux, Eric ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b AMGEN INC   (United States)

^c INDIAN INSTITUTE OF SCIENCE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DICHLOROPHENETHYLAMINE; BINDING PROTEIN; BIOGENIC AMINE TRANSPORTER; CHLORIDE ION; COCAINE; COCAINE DERIVATIVE; DEXAMPHETAMINE; DOPAMINE; DOPAMINE DERIVATIVE; DOPAMINE TRANSPORTER; LIGAND; METHAMPHETAMINE; NEUROTRANSMITTER; PSYCHOSTIMULANT AGENT; SODIUM ION; UNCLASSIFIED DRUG; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ANTIDEPRESSANT AGENT; CENTRAL STIMULANT AGENT; CHLORIDE; PHENETHYLAMINE DERIVATIVE; SODIUM;

CRYSTAL STRUCTURE; DRUG; INHIBITOR; MEMBRANE; MOLECULAR ANALYSIS; NEUROLOGY; SUBSTRATE; X-RAY SPECTROSCOPY;

ANIMAL CELL; ARTICLE; BILAYER MEMBRANE; BINDING SITE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DROSOPHILA MELANOGASTER; HEK293 CELL LINE; LIGAND BINDING; MOLECULAR RECOGNITION; NERVE CELL PLASTICITY; NEUROCHEMISTRY; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; X RAY CRYSTALLOGRAPHY; ANALOGS AND DERIVATIVES; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; METABOLISM; PROTEIN STABILITY;

DROSOPHILA MELANOGASTER;

ANIMALS; ANTIDEPRESSIVE AGENTS; BINDING SITES; CENTRAL NERVOUS SYSTEM STIMULANTS; CHLORIDES; COCAINE; CRYSTALLOGRAPHY, X-RAY; DEXTROAMPHETAMINE; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DROSOPHILA MELANOGASTER; LIGANDS; METHAMPHETAMINE; MODELS, MOLECULAR; MOLECULAR CONFORMATION; NEUROTRANSMITTER AGENTS; PHENETHYLAMINES; PROTEIN STABILITY; SODIUM;

EID: 84930204469     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature14431     Document Type: Article

References (60)

1. Carlsson, A., Lindqvist, M. & Magnusson, T. 3, 4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 180, 1200 (1957).
2. Twarog, B. M. & Page, I. H. Serotonin content of some mammalian tissues and urine and a method for its determination. Am. J. Physiol. 175, 157-161 (1953).
3. von Euler, U. Sympathin in adrenergic nerve fibres. J. Physiol. (Lond.) 105, 26 (1946).
4. Hertting, G. & Axelrod, J. Fate of tritiated noradrenaline at the sympathetic nerve-endings. Nature 192, 172-173 (1961).
5. Iversen, L. L. Role of transmitter uptake mechanisms in synaptic neurotransmission. Br. J. Pharmacol. 41, 571-591 (1971).
6. Iversen, L. L. & Kravitz, E. A. Sodium dependence of transmitter uptake at adrenergic nerve terminals. Mol. Pharmacol. 2, 360-362 (1966).
7. Kristensen, A. S. et al. SLC6 neurotransmitter transporters: structure, function, and regulation. Pharmacol. Rev. 63, 585-640 (2011).
8. Pramod, A. B., Foster, J., Carvelli, L. & Henry, L. K. SLC6 transporters: structure, function, regulation, disease association and therapeutics. Mol. Aspects Med. 34, 197-219 (2013).
9. Penmatsa, A., Wang, K. H. & Gouaux, E. X-ray structure of dopamine transporter elucidates antidepressant mechanism. Nature 503, 85-90 (2013).
10. Koldsø, H., Christiansen, A.B., Sinning, S. & Schiøtt, B. Comparative modelingofthe human monoamine transporters: similarities in substrate binding. ACS Chem Neurosci 4, 295-309 (2013).
11. Yamashita, A., Singh, S. K., Kawate, T., Jin, Y. & Gouaux, E. Crystal structure of a bacterialhomologueofNa1/Cl--dependent neurotransmitter transporters. Nature 437, 215-223 (2005).
12. Beuming, T., Shi, L., Javitch, J. A. & Weinstein, H. A comprehensive structure-based alignmentofprokaryoticand eukaryotic neurotransmitter/Na1symporters (NSS) aids in the use of the LeuT structure to probe NSS structure and function. Mol. Pharmacol. 70, 1630-1642 (2006).
13. Gu, H., Wall, S. C. & Rudnick, G. Stable expression of biogenic amine transporters reveals differences in inhibitor sensitivity, kinetics, and ion dependence. J. Biol. Chem. 269, 7124-7130 (1994).
14. Kilty, J. E., Lorang, D. & Amara, S. G. Cloning and expression of a cocaine-sensitive rat dopamine transporter. Science 254, 578-579 (1991).
15. Kurian, M. A. et al. Homozygous loss-of-function mutations in the gene encoding the dopamine transporter are associated with infantile parkinsonism-dystonia. J. Clin. Invest. 119, 1595-1603 (2009).
16. Giros, B., Jaber, M., Jones, S. R., Wightman, R. M. & Caron, M. G. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379, 606-612 (1996).
17. Mergy, M. A. et al. The rare DAT coding variant Val559 perturbs DA neuron function, changes behavior, and altersinvivo responses to psychostimulants. Proc. Natl Acad. Sci. USA 111, E4779-E4788 (2014).
18. Zaczek, R., Culp, S., Goldberg, H., McCann, D. J. & De Souza, E. B. Interactions of [3H]amphetamine with rat brain synaptosomes. I. Saturable sequestration. J. Pharmacol. Exp. Ther. 257, 820-829 (1991).
19. Bönisch, H. The transport of (1)-amphetamine by the neuronal noradrenaline carrier. Naunyn Schmiedebergs Arch. Pharmacol. 327, 267-272 (1984).
20. Eshleman, A. J., Henningsen, R.A., Neve, K.A. & Janowsky, A. Releaseof dopamine via the human transporter. Mol. Pharmacol. 45, 312-316 (1994).
21. Goodwin, J. S. et al. Amphetamine and methamphetamine differentially affect dopamine transporters in vitro and invivo. J. Biol. Chem. 284, 2978-2989 (2009).
22. Sitte, H. H. et al. Carrier-mediated release, transport rates, and charge transfer induced by amphetamine, tyramine, and dopamine in mammalian cells transfectedwith the human dopaminetransporter.J. Neurochem. 71, 1289-1297 (1998).
23. Sonders, M. S., Zhu, S. J., Zahniser, N. R., Kavanaugh, M. P. & Amara, S. G. Multiple ionic conductancesofthe human dopamine transporter: the actionsofdopamine and psychostimulants. J. Neurosci. 17, 960-974 (1997).
24. Wall, S. C., Gu, H. & Rudnick, G. Biogenic amine flux mediated by cloned transporters stably expressed in cultured cell lines: amphetamine specificity for inhibition and efflux. Mol. Pharmacol. 47, 544-550 (1995).
25. Beuming, T. et al. The binding sites for cocaine and dopamine in the dopamine transporter overlap. Nature Neurosci. 11, 780-789 (2008).
26. Bisgaard, H. et al. The binding sites for benztropines and dopamine in the dopamine transporter overlap. Neuropharmacology 60, 182-190 (2011).
27. Sørensen, G. et al. Neuropeptide Y Y5 receptor antagonism attenuates cocaine-induced effects in mice. Psychopharmacology (Berl.) 222, 565-577 (2012).
28. Richelson, E. & Pfenning, M. Blockadebyantidepressantsand related compounds of biogenic amine uptake into rat brain synaptosomes: most antidepressants selectively block norepinephrine uptake. Eur. J. Pharmacol. 104, 277-286 (1984).
29. Sørensen, L. et al. Interaction of antidepressants with the serotonin and norepinephrine transporters: mutational studies of the S1 substrate binding pocket. J. Biol. Chem. 287, 43694-43707 (2012).
30. Dahal, R. A. et al. Computational and biochemical docking of the irreversible cocaine analog RTI 82 directly demonstrates ligand positioning in the dopamine transporter central substrate binding site. J. Biol. Chem. 289, 29712-29727 (2014).
31. Pörzgen, P., Park, S. K., Hirsh, J., Sonders, M. S. & Amara, S. G. The antidepressant-sensitive dopamine transporter inDrosophila melanogaster:a primordial carrier for catecholamines. Mol. Pharmacol. 59, 83-95 (2001).
32. Abdul-Hussein, S., Andrell, J. & Tate, C. G. Thermostabilisation of the serotonin transporter in a cocaine-bound conformation. J. Mol. Biol. 425, 2198-2207 (2013).
33. Wang, H. et al. Structural basis for action by diverse antidepressants on biogenic amine transporters. Nature 503, 141-145 (2013).
34. Huang, X. & Zhan, C. G. How dopamine transporter interacts with dopamine: insights from molecular modeling and simulation. Biophys. J. 93, 3627-3639 (2007).
35. Kitayama, S. et al. Dopamine transporter site-directedmutations differentially alter substrate transport andcocaine binding. Proc. Natl Acad. Sci. USA 89, 7782-7785 (1992).
36. Han, D. D. & Gu, H. H. Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacol. 6, 6 (2006).
37. Newman, A. H., Zou, M. F., Ferrer, J. V. & Javitch, J. A. [3H]MFZ 2-12: a novel radioligandfor thedopaminetransporter. Bioorg. Med. Chem. Lett. 11, 1659-1661 (2001).
38. Kazmier, K. et al. Conformational dynamics of ligand-dependent alternating access in LeuT. Nature Struct. Mol. Biol. 21, 472-479 (2014).
39. Krishnamurthy, H. & Gouaux, E.X-ray structuresofLeuTinsubstrate-freeoutward-open and apo inward-open states. Nature 481, 469-474 (2012).
40. Hong, W. C. & Amara, S. G. Membrane cholesterol modulates the outward facing conformation of the dopamine transporter and alters cocaine binding. J. Biol. Chem. 285, 32616-32626 (2010).
41. Zhao, Y. et al. Substrate-modulated gating dynamics in a Na1-coupled neurotransmitter transporter homologue. Nature 474, 109-113 (2011).
42. Malinauskaite, L. et al. A mechanism for intracellular release of Na1 by neurotransmitter/sodium symporters. Nature Struct. Mol. Biol. 21, 1006-1012 (2014).
43. Perez, C., Koshy, C., Yildiz, O. & Ziegler, C. Alternating-access mechanism in conformationally asymmetric trimersofthe betaine transporter BetP. Nature490, 126-130 (2012).
44. Weyand, S. et al. Structure and molecular mechanism of a nucleobase-cation-symport-1 family transporter. Science 322, 709-713 (2008).
45. Loland, C. J. et al. Relationship between conformational changes in the dopamine transporter and cocaine-like subjective effects of uptake inhibitors. Mol. Pharmacol. 73, 813-823 (2008).
46. Lee, S. H. et al. Importance of valine at position 152 for the substrate transport and 2b-carbomethoxy-3b-(4-fluorophenyl)tropane binding of dopamine transporter. Mol. Pharmacol. 57, 883-889 (2000).
47. Chen, J.G., Sachpatzidis, A. & Rudnick, G. The third transmembranedomainofthe serotonin transporter contains residues associated with substrate and cocaine binding. J. Biol. Chem. 272, 28321-28327 (1997).
48. Singh, S. K., Piscitelli, C.L., Yamashita, A. & Gouaux, E. A competitive inhibitor traps LeuT in an open-to-out conformation. Science 322, 1655-1661 (2008).
49. Claxton, D. P. et al. Ion/substrate-dependent conformational dynamics of a bacterial homolog of neurotransmitter:sodium symporters. Nature Struct. Mol. Biol. 17, 822-829 (2010).
50. Schmitt, K. C., Rothman, R. B. & Reith, M. E. Nonclassical pharmacology of the dopamine transporter: atypical inhibitors, allosteric modulators, and partial substrates. J. Pharmacol. Exp. Ther. 346, 2-10 (2013).
51. Reeves, P.J., Callewaert, N., Contreras, R. & Khorana, H.G. Structure and function in rhodopsin: high-level expression of rhodopsin with restricted and homogeneous N-glycosylation by a tetracycline-inducible N-acetylglucosaminyltransferase I-negative HEK293S stable mammalian cell line. Proc. Natl Acad. Sci. USA 99, 13419-13424 (2002).
52. Goehring, A. et al. Screening and large-scale expression of membrane proteins in mammalian cells for structural studies. Nature Protocols 9, 2574-2585 (2014).
53. Otwinowski, Z., &. Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307-326 (1997).
54. Kabsch, W. XDS. Acta Crystallogr. D 66, 125-132 (2010).
55. McCoy, A.J. et al. Phaser crystallographic software.J. Appl. Crystallogr. 40, 658-674 (2007).
56. Afonine, P. V. et al. Towards automated crystallographic structure refinement with phenix.refine. Acta Crystallogr. D 68, 352-367 (2012).
57. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D 60, 2126-2132 (2004).
58. Quick, M. & Javitch, J. A. Monitoring the function of membrane transport proteins in detergent-solubilized form. Proc. Natl Acad. Sci. USA 104, 3603-3608 (2007).
59. Eshleman, A. J. et al. Metabolism of catecholamines by catechol-O-methyltransferase in cells expressing recombinant catecholamine transporters. J. Neurochem. 69, 1459-1466 (1997).
60. Dehnes, Y. et al. Conformational changes in dopamine transporter intracellular regions upon cocaine binding and dopamine translocation. Neurochem. Int. 73, 4-15 (2014).